1. Home
  2. AMTB vs PHVS Comparison

AMTB vs PHVS Comparison

Compare AMTB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$20.93

Market Cap

857.5M

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$25.30

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
PHVS
Founded
1979
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
857.5M
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AMTB
PHVS
Price
$20.93
$25.30
Analyst Decision
Buy
Buy
Analyst Count
4
9
Target Price
$22.25
$39.44
AVG Volume (30 Days)
239.0K
245.7K
Earning Date
01-22-2026
11-12-2025
Dividend Yield
1.76%
N/A
EPS Growth
N/A
N/A
EPS
1.59
N/A
Revenue
$388,504,000.00
N/A
Revenue This Year
$61.42
N/A
Revenue Next Year
$2.10
N/A
P/E Ratio
$12.87
N/A
Revenue Growth
51.98
N/A
52 Week Low
$15.62
$11.51
52 Week High
$24.40
$29.80

Technical Indicators

Market Signals
Indicator
AMTB
PHVS
Relative Strength Index (RSI) N/A 49.30
Support Level N/A $25.28
Resistance Level N/A $26.68
Average True Range (ATR) 0.00 1.50
MACD 0.00 -0.06
Stochastic Oscillator 0.00 35.14

Price Performance

Historical Comparison
AMTB
PHVS

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: